Management of Raynaud’s Phenomenon

John D. Pauling

How do I Recognize and Treat the VEXAS Syndrome?

Cleveland Clinic Rheumatology

P. Grayson

Cleveland Clinic Rheumatic Case Studies: 32 y/o Male w/ Inflammatory…

Cleveland Clinic Rheumatology

L. Calabrese, J. Gelfand, C. Oddis, J. Cush, A. Kavanaugh, R. Hajj-Ali

Giant Cell Arteritis in the Arab Region With a Focus on Jordan

Fatima Al Naimat

Myths and Misconceptions ANCA Associated Vasculitis

RheumNow

M. Putman

Rheumatology Update for the Generalist in 2024

McMaster University Department of Medicine

R. Mirza

How Does the Treatment of Behçet’s Disease Differ Based on Disease M…

Cleveland Clinic Rheumatology

G. Hatemi

What’s Causing the Inflammatory Arthritis & Weight Loss? Why Did a R…

Cleveland Clinic Rheumatology Case Studies

A. Brown

70 y/o Male With Seropositive RA, ANCA Vasculitis, and ILD: Would An…

Keck School of Medicine of USC

C. Chen

Is There Still a Role for Conventional Immunosuppressive Agents in A…

Cleveland Clinic Rheumatology

C. Langford

Maintenance Rituximab in ANCA-Associated Vasculitis: Dose, Frequency…

Cleveland Clinic Rheumatology

R. Smith

Diagnosis of ANCA-Associated Vasculitis: Use of ANCA Testing

North Carolina Rheumatology Association

P. Seo

Complement and ANCA Vasculitis

Cleveland Clinic Rheumatology

A. Brown

To B or Not to B - CAR-T Cells Enter the Treatment Arena of IMIDS

William Rigby

Vasculitis Treatment Case Presentation

Cleveland Clinic Rheumatology

A. Brown

ANCA and Endocarditis

Cleveland Clinic Rheumatology

A. Brown

72 y/o Female With Giant Cell Arteritis, Polymyalgia Rheumatica, and…

Vanderbilt University Medical Center (VUMC)

K. Byram

When Should Biologic Agents be Introduced in Giant Cell Arteritis an…

Cleveland Clinic Rheumatology

K. Warrington

Vasculitis & Pregnancy

RheumNow

C. Sims

Bartonella for the Rheumatologist

Cleveland Clinic Rheumatology and Immunology Series

A. Brown